TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30088198
Drug: HBsAg-based recombinant
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-based recombinant vaccine administered every 8 weeks for 48 weeks (seven doses)
Study: 30088336
Drug: Low-energy diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy diet (LED) 3.4 MJ/810 kcal daily for 8 weeks
Study: 30088802
Drug: Tidal breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal breathing measurements before and after inhaled albuterol (1 week before anticipated hospital discharge)
Study: 30088802
Drug: Bronchodilator response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bronchodilator response
Study: 30089406
Drug: Sodium <20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium <20 mmol/L
Study: 30089406
Drug: Sodium >20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium >20 mmol/L
Study: 30089457
Drug: Hypo-fractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-fractionated radiotherapy at 40.0 Gy/2.5 Gy with concurrent S-1 at 80 mg/m2
Study: 30089523
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication use review
Study: 30091207
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) therapy followed by Non-Ablative Fractionated Laser (NAFL) treatment
Study: 30092965
Drug: Anthracycline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline therapy (Doxorubicin)
Study: 30093531
Drug: Thioridazine (TDZ)
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine (TDZ) 25 mg every 6 hours for 21 days
Study: 30093531
Drug: Thioridazine (TDZ)
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine (TDZ) 50 mg every 6 hours for 21 days
Study: 30093531
Drug: Thioridazine (TDZ)
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine (TDZ) 100 mg every 6 hours for 21 days
Study: 30093866
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with vitamin D (10 μg/day)
Study: 30094070
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic (4-cycle schedule, ≤24 doses)
Study: 30095576
Drug: Increased vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased vitamin D dosage according to NACFF guidelines
Study: 30095603
Drug: XEN gel
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN gel implant surgery (combined XEN+cataract surgery or standalone XEN surgery)
Study: 30096071
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine (YF-17D strain)
Study: 30096144
Drug: Treatment Self-Regulation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Self-Regulation Questionnaire (TSRQ)
Study: 30098602
Drug: Transfused RBC
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfused RBC characteristics (irradiation and metabolism)
Study: 30098707
Drug: Rivaroxaban 15mg
Normalized name: RIVAROXABAN 15MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 15mg administered twice daily for 90 days
Study: 30099150
Drug: Intensive mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive mobilization under analgesic gas (equimolar mixture of oxygen and nitrous oxide)
Study: 30099150
Drug: Intensive mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive mobilization under placebo gas (sham gas administration)
Study: 30099150
Drug: Intensive mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive mobilization under analgesic gas
Study: 30099350
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for eight weeks
Study: 30099396
Drug: Laparoscopic distal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic distal gastrectomy (LDG) after neoadjuvant chemotherapy
Study: 30099396
Drug: Open distal
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open distal gastrectomy (ODG) after neoadjuvant chemotherapy
Study: 30099397
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - intravenous infusion of 10 mL (1 g) immediately followed by three identical infusions over 8 hours (total dose of 4 g over 24 hours)
Study: 30099397
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) - intravenous infusion of 40 mL over 24 hours
Study: 30099641
Drug: Denosumab administration
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab administration
Study: 30099818
Drug: Sym004 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 6 mg/kg/wk
Study: 30099818
Drug: Sym004 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 9 mg/kg loading/6 mg/kg/wk
Study: 30099818
Drug: Sym004 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 12 mg/kg/wk
Study: 30099818
Drug: Sym004 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 18 mg/kg biweekly
Study: 30099818
Drug: Sym004 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 at the dose recommended from Part A (12 mg/kg/wk) in Part B
Study: 30101351
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of one-carbon metabolism nutrients
Study: 30101387
Drug: BGJ398 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BGJ398 daily 3 weeks on, 1 week off (dose range: 25 - 75 mg)
Study: 30101387
Drug: BGJ398 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BGJ398 daily 1 week on, 3 weeks off (dose range: 75 - 100 mg)
Study: 30101387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BGJ398 and imatinib
Study: 30101412
Drug: Acid suppression
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid suppression therapy
Study: 30102205
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT) followed by gemcitabine, dexamethasone, and cisplatin (GDP)
Study: 30102789
Drug: Teriparatide treatment
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide treatment for 2 years
Study: 30103979
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapies (ACE inhibitors, ARBs, β blockers, MRAs) at recommended doses
Study: 30103979
Drug: Uptake of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptake of guideline-directed medical therapies
Study: 30464579
Drug: duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: duloxetine 60 mg/day
Study: 30105657
Drug: Micafungin (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (treatment for at least 1 week)
Study: 30105657
Drug: Micafungin (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (treatment for less than 1 week)
Study: 30105657
Drug: Micafungin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (daily dose 50-100 mg)
Study: 30105657
Drug: Micafungin (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (other daily doses)
Study: 30105951
Drug: Buparlisib, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib, 100 mg daily
Study: 30106639
Drug: Serum biomarker
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum biomarker signature derived from a case-control study using an antibody microarray platform.
Study: 30107868
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (C1-INH) 40 IU/kg twice weekly
Study: 30107868
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (C1-INH) 60 IU/kg twice weekly
Study: 30108004
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam radiation therapy (PRT)
Study: 30109845
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 882 mg intramuscular every 4 weeks
Study: 30109845
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 441 mg intramuscular every 4 weeks
Study: 30109845
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with aripiprazole lauroxil
Study: 30109845
Drug: Initial injections
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial injections of aripiprazole lauroxil
Study: 30110589
Drug: Ibalizumab (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibalizumab (2000 mg loading dose, then 800 mg every 14 days)
Study: 30111186
Drug: No second-generation
Normalized name: Second-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: No second-generation antipsychotic exposure
Study: 30115015
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income level < $1500
Study: 30115015
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income level $1500-4500
Study: 30115015
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income level > $4500 (reference)
Study: 30115541
Drug: Cladribine plus
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine plus low-dose cytarabine alternating with decitabine for up to 18 cycles (induction therapy: cladribine 5 mg/m²).
Study: 30115541
Drug: Cladribine plus
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine plus low-dose cytarabine alternating with decitabine.
Study: 30115596
Drug: Bendamustine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (70 mg/m²) followed by obinutuzumab and venetoclax
Study: 30115734
Drug: Itacitinib 300
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 300 mg plus chemotherapy
Study: 30117149
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m² weekly for 4 cycles
Study: 30117149
Drug: Bendamustine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (specific dosage not mentioned)
Study: 30119925
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy (received by 402 patients, 48.4%)
Study: 30120161
Drug: Regorafenib administered
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib administered daily for 3 weeks of each 4-week cycle until disease progression or other reason.
Study: 30120518
Drug: AbobotulinumtoxinA (Dysport)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (Dysport) injection cycles
Study: 30120956
Drug: Wet heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet heparin suction
Study: 30120956
Drug: Dry heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry heparin suction
Study: 30120956
Drug: Dry heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry heparin
Study: 30121602
Drug: Dabrafenib in
Normalized name: Product containing dabrafenib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib in combination with trametinib
Study: 30121602
Drug: Dabrafenib monotherapy
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib monotherapy or combination therapy
Study: 30121827
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg with loading dose
Study: 30121827
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg without loading dose
Study: 30121938
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (RT) at a maximum tolerated dose (MTD) of 20 Gy delivered in 2 days, twice daily.
Study: 30122202
Drug: EORTC QLQ-C30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer-Core Quality of Life Questionnaire, version 3.0); range 0-100
Study: 30122926
Drug: Asenapine 2.5
Normalized name: asenapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 2.5 mg BID
Study: 30122926
Drug: Asenapine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5.0 mg BID
Study: 30122926
Drug: Asenapine 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 10.0 mg BID
Study: 30123524
Drug: Positive Mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Mental Imagery Training (PMIT) + Treatment as Usual (TAU)
Study: 30123524
Drug: Cognitive Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Control Training (CCT) + Treatment as Usual (TAU)
Study: 30123523
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (targeted to heart rate 80-90/min)
Study: 30123673
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice daily during the first 3 cycles of VCD induction therapy
Study: 30123673
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily during the first 3 cycles of VCD induction therapy
Study: 30123846
Drug: Herbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formulation (HB)
Study: 30126674
Drug: Pfs25 VLP-FhCMB
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25 VLP-FhCMB vaccine combined with Alhydrogel® adjuvant
Study: 30126674
Drug: Pfs25 VLP-FhCMB
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25 VLP-FhCMB vaccine
Study: 30126765
Drug: Enzalutamide 1L
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 1L treatment (chemo-naive)
Study: 30126765
Drug: Enzalutamide 2L
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 2L treatment (post-docetaxel or -abiraterone)
Study: 30126765
Drug: Enzalutamide 3L
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 3L or 4L treatment
Study: 30126765
Drug: Enzalutamide 3L
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 3L or 4L treatment (fatigue)
Study: 30126861
Drug: Paclitaxel (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (70 mg/m2)
Study: 30126891
Drug: Multifaceted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted medication reconciliation quality improvement intervention
Study: 30126953
Drug: ETX2514SUL (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETX2514SUL (combination of ETX2514 and sulbactam)
Study: 30127621
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of oral osimertinib, oral temozolomide, intrathecal cytarabine, and whole-brain radiation therapy
Study: 30128164
Drug: Individualised telemedicine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualised telemedicine cognitive behavioural therapy (CBT)-based intervention
Study: 30128316
Drug: Drisapersen 6
Normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drisapersen 6 mg/kg/week for 24 weeks
Study: 30128316
Drug: Drisapersen 3
Normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drisapersen 3 mg/kg/week for 24 weeks
Study: 30128502
Drug: PVX-410 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVX-410 vaccine (0.4 mg total, 0.1 mg/peptide, n=3) or (0.8 mg total, 0.2 mg/peptide, n=9) biweekly via subcutaneous injection, plus 0.5 mL (1 mg) poly-ICLC (2 mg/mL) via intramuscular injection with each dose.
Study: 30128502
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PVX-410 vaccine with lenalidomide (25 mg orally daily for three 21-day cycles, n=10).
Study: 30128502
Drug: PVX-410 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVX-410 vaccine alone (monotherapy).
Study: 30128605
Drug: Intravitreal decorin
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal decorin 200 μg
Study: 30128605
Drug: Intravitreal decorin
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal decorin 400 μg
Study: 30129045
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance (RM) after R-CHOP-based induction therapy
Study: 30129045
Drug: R-CHOP-based induction
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP-based induction therapy
Study: 30131059
Drug: Inconsistently moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inconsistently moderate drinkers (males: 1-168 g ethanol/week; females: 1-112 g ethanol/week)
Study: 30131748
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy
Study: 30134131
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg) every 3 weeks for up to four doses, followed by Nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects
Study: 30134131
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg)
Study: 30135755
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioural therapy (CCBT) with Internet Support Group (ISG)
Study: 30135755
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioural therapy (CCBT) without Internet Support Group (ISG)
Study: 30135764
Drug: Unguided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided internet-delivered cognitive-behavioral therapy for insomnia (ICBTi)
Study: 30135764
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Cognitive-behavioral therapy for insomnia)
Study: 30137238
Drug: TFV disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFV disoproxil fumarate (TDF)-based therapy
Study: 30137396
Drug: Homeostasis model
Normalized name: CALCIUM HOMEOSTASIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostasis model assessment for insulin resistance
Study: 30137406
Drug: Higher bioavailable
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher bioavailable testosterone, free testosterone, dehydroepiandrosterone (DHEA), and lower sex hormone-binding globulin (SHBG) levels
Study: 30137598
Drug: Daily sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sleep duration and variability measured by wrist actigraphy
Study: 30138022
Drug: brief cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief cognitive-behavioral therapy (bCBT)
Study: 30139372
Drug: Clofazimine (CFZ)
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine (CFZ) administered orally for 5 days
Study: 30139372
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally for 5 days
Study: 30139779
Drug: CXCR2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CXCR2 antagonist danirixin
Study: 30139840
Drug: Linsitinib 450
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsitinib 450 mg daily on days 1-3 every 7 days and irinotecan 125 mg/m²
Study: 30139840
Drug: Linsitinib 400
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsitinib 400 mg and irinotecan 100 mg/m²
Study: 30139897
Drug: Medication intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intake
Study: 30139903
Drug: MK-7 (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 (720 µg/day) supplemented by vitamin D (25 µg/day)
Study: 30139903
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (no active treatment)
Study: 30142084
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week supervised exercise therapy alone